# Nucleix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nucleix

- Industry: Healthcare Specialists
- Headquarters: Rehovot, Israel
- Website: www.nucleix.com
- Total disclosed funding: $3M
- Latest round: Seed (May 23, 2016)
- Investors on record: 2

## About

Nucleix, based in Rehovot, Israel, specializes in innovative diagnostic solutions for early cancer detection, focusing on non-invasive testing methods to enhance patient care.Nucleix is a diagnostic solutions provider established in 2008 in Rehovot, Israel. The company was founded by Adam Wasserstrom and Danny Frumkin, with Chris Hibberd currently serving as CEO. Nucleix has secured USD 22.00 mn in total funding, with its latest funding round led by Sands Capital Ventures. The company has completed 6 deals since inception.Nucleix specializes in innovative diagnostic solutions aimed at early cancer detection, including its flagship product, Bladder EpiCheck®. This non-invasive test detects both primary and recurrent bladder cancer and upper tract urinary cancer, thus serving as a vital tool for at-risk patients. Bladder EpiCheck® has received CE marking for sale in Europe and FDA clearance for monitoring bladder cancer recurrence in the United States. The company is also focused on developing a blood test for early-stage lung cancer detection, primarily targeting high-risk individuals, while collaborating with leading medical centers and laboratories across Europe and North America.Nucleix's revenue model is centered around the sales of its diagnostic products, particularly Bladder EpiCheck®, which plays a crucial role in monitoring non-muscle invasive bladder cancer recurrence. The company engages in direct transactions with healthcare providers, hospitals, and laboratories, ensuring a streamlined delivery of its testing solutions. Their pricing strategy reflects the advanced technology behind their diagnostic offerings, which are essential in cancer management and monitoring.Nucleix plans to utilize its recent funding of USD 22.00 mn to advance the development of new products, including a blood test for early-stage lung cancer detection. The company is also targeting expansion into new markets, with a focus on broadening its presence in Europe and North America by 2025. The recent investment from DSC Investment will support these initiatives and enhance its research and development efforts.

## Funding rounds

- Seed, May 23, 2016, $3M — OrbiMed Advisors, Aurum Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed
- Aurum Ventures (https://capitalatlas.ai/funds/aurum-ventures) — Seed